• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Artificial DMEK could help tackle endothelial donor tissue shortage

Digital EditionOphthalmology Times: November 15, 2021
Volume 46
Issue 19

New acrylic implant provides option for patients with endothelial dysfunction.

Victor A. Augustin,
Maximilian K. Köppe
Gerd U. Auffarth

Special to Ophthalmology Times®

More than 115 years ago, in 1905, Eduard Zirm successfully performed the first corneal transplantation.1 Penetrating keratoplasties remained the gold standard for the treatment of a variety of corneal conditions for much of the 20th century.

In 1998, Melles and colleagues successfully attached a posterior lamellar graft consisting of stroma, Descemet membrane, and endothelium to the posterior surface of the cornea, which initiated a new era in the treatment of corneal diseases primarily affecting the endothelium.2

In 2006, Melles et al first described the selective transplantation of the endothelium and Descemet membrane (EDM).3

Descemet membrane endothelial keratoplasty (DMEK) involves the surgical removal of the diseased endothelial layer as well as the diseased Descemet membrane from the posterior corneal stroma.4

In comparison with traditional full-thickness or penetrating keratoplasty, DMEK gives the patient faster visual recovery, better refractive outcome and tectonic integrity.5-7

Endothelial keratoplasties such as DMEK are the gold standard in endothelial dysfunction,8 including Fuchs endothelial dystrophy,8 pseudophakic bullous keratopathy,9 graft failure after penetrating or endothelial keratoplasty,9 pseudoexfoliation syndrome keratopathy,9 and endothelial decompensation due to congenital glaucoma.10

Known complications such as primary or secondary graft failure, immunological graft rejection, and interface keratitis remain a challenge and can have a negative impact on the procedure.8,11,12

Donor tissue preparation and insertion into the anterior chamber are routine. However, rupture of the EDM during preparation can lead to graft loss, which can delay surgical intervention and disrupt organizational processes in a clinic.12

Furthermore, prolonged or careless manipulation of the EDM in the anterior chamber can lead to significant endothelial loss with potential primary or (early) secondary graft failure.12

According to a report published by the German Keratopathy Registry, the majority of keratoplasties performed these days are posterior lamellar keratoplasties; only 30% are penetrating keratoplasties.13

Additionally, because human donor corneas are in constant short supply,10 there is a need for alternative, universally available treatment options.

In 2018, Kinoshita et al proposed the injection of cultured human corneal endothelial cells supplemented with a ρ-associated protein kinase inhibitor into the anterior chamber to increase corneal endothelial cell density.14

A 5-year follow-up published in 2020 by Numa et al confirmed the safety and efficacy of this approach, however, it was tested only in a very small number of patients and further long-term data do not yet exist.15

Figure 1. The implant

Another technique with no need for donor corneal tissue is Descemet membrane stripping only (DSO) with or without the topical treatment of ρ kinase inhibitors.

DSO involves removing a small area of central endothelium that has become dysfunctional without performing an endothelial keratoplasty.16

This method was successful in a small number of patients with Fuchs endothelial dystrophy but its long-term efficacy has yet to be evaluated.16

A very limited number of patients are eligible for this method because of the need for healthy peripheral endothelial cells as well as central corneal guttae.

A novel approach involves the implantation of an artificial endothelial layer to the posterior aspect of the cornea.

The EndoArt (EyeYon Medical) is a hydrophilic acrylic, dome-shaped permanent implant, 6 mm in diameter and 50 µm thick, specifically designed to replace the diseased corneal Descemet-endothelium layer.

Implanting the lamella on the posterior surface of the cornea replaces the diseased endothelium and impedes the transfer of fluids into the central stroma.

By covering about 40% of the back corneal surface, blocking the influx of fluids as well as epithelial evaporation leads to a reduction in corneal oedema to restore corneal homeostasis.

This artificial endothelial layer—which has been awarded a breakthrough therapy designation by the FDA, China’s Innovative Device Status, and CE certification—could provide a paradigm shift in the treatment of patients with endothelial failure while eliminating the need for human donor tissues.

The Department of Ophthalmology of the University Eye Clinic in Heidelberg, Germany, was one of the first centers to implant this innovative device, with patients having completed 2 years of follow-up.

The initial long-term evaluations are promising and demonstrate good safety and efficacy results. The implant is undergoing a first-in-human, multicenter trial across Europe and Asia.

FIGURE 2. Slit-lamp pictures and OCT images before (A+C) and 12 weeks after implantation (B+D). Significant corneal oedema is shown in A and quantified via OCT in C. Marked resolution of corneal oedema 12 weeks after implantation is shown in B. Significant reduction in corneal thickness is measured by means of OCT in D. The white arrows show the outlines of the implant on the posterior surface of the cornea in B and D.

Figure 2: Slit-lamp pictures and OCT images before (A+C) and 12 weeks after implantation (B+D). Significant corneal oedema is shown in A and quantified via OCT in C. Marked resolution of corneal oedema 12 weeks after implantation is shown in B. Significant reduction in corneal thickness is measured by means of OCT in D. The white arrows show the outlines of the implant on the posterior surface of the cornea in B and D. (Images courtesy of IVCRC Heidelberg)

Surgical technique
A 9-mm ring marks the central corneal surface to outline the peripheral extent of the Descemet membrane excision.

With 2 paracentesis incisions made at the 10 o’clock and 2 o’clock positions, the implant is folded into the cartridge of an IOL-injector and is then injected through a 2.2-mm clear cornea incision into the anterior chamber of the eye.

The lamella then unfolds itself and is manually positioned onto the posterior corneal surface using an air bubble technique, similar to a DMEK procedure.

Unlike a human donor lamella, the implant can be touched and moved by the surgeon using a cannula without compromising its function.

The experienced corneal surgeon who is already familiar with the DMEK procedure should be able to place the implant without the need for extra training. Cataract surgeons may require a few extra training sessions.

A 79-year-old man presented to our clinic after complicated cataract surgery at a private practice. DMEK was not a treatment option because of his wide and non–light reactive pupil and anterior synechiae. The patient was complaining of decreased vision.

On examination, the patient showed significant corneal oedema with corneal bullae and reminiscent lens material in the anterior chamber of the left eye. The patient perceived finger count with the left eye. An epiretinal gliosis was present on both eyes, and the patient had received cryotherapy on the left eye due to a retinal tear 10 years earlier.

Retinal optical coherence tomography imaging revealed a preexisting macular oedema, which is currently the limiting factor for visual improvement. The patient is being treated with peribulbar injections of steroids, and further visual improvement is expected.

This technique shows that an artificial endothelial layer is feasible for treatment of patients with endothelial dysfunction. This shows promise for overcoming the worldwide shortage of donor endothelial tissue.

Furthermore, in cases where endothelial keratoplasty may not be possible, this may be a readily available treatment option.

About the authors

Victor A. Augustin, MD

E: vic.augustin@googlemail.com
The authors are based at the David J. Apple International Laboratory for Ocular Pathology and International Vision Correction Research Centre, Department of Ophthalmology, University of Heidelberg, Germany. Augustin and Köppe declare no conflicts of interest. Auffarth reports grants, personal fees, nonfinancial support, and consulting fees from Johnson & Johnson and Alcon; grants, personal fees, and nonfinancial support from Carl Zeiss Meditec, Hoya, Kowa, Oculentis/Teleon, Rayner, Santen, Sifi, and Ursapharm; grants and personal fees from Biotech, Oculus, and EyeYon; and grants from AcuFocus, Anew, Contamac, Glaukos, PhysIOL, and Rheacell, outside the submitted work.



1. Zirm EK. Eine erfolgreiche totale Keratoplastik (a successful total keratoplasty). Refract Corneal Surg. 1989;5(4):258-261.

2. Melles GR, Eggink FA, Lander F, et al. A surgical technique for posterior lamellar keratoplasty. Cornea. 1998;17(6):618-626. doi:10.1097/00003226-199811000-00010

3. Melles GR, Ong TS, Ververs B, et al. Descemet membrane endothelial keratoplasty (DMEK). Cornea. 2006;25(8):987-990. doi:10.1097/01.ico.0000248385.16896.34

4. Kruse FE, Schrehardt US, Tourtas T. Optimizing outcomes with Descemet’s membrane endothelial keratoplasty. Curr Opin Ophthalmol. 2014;25(4):325-334. doi:10.1097/ICU.0000000000000072

5. Dapena I, Ham L, Melles GRJ. Endothelial keratoplasty: DSEK/DSAEK or DMEK—the thinner the better? Curr Opin Ophthalmol. 2009;20:299-307.

6. Melles GR, Ong TS, Ververs B, van der Wees J. Preliminary clinical results of Descemet membrane endothelial keratoplasty. Am J Ophthalmol. 2008;145:222-227.

7. Price MO, Price FW Jr. Endothelial keratoplasty – a review. Clin Exp Ophthalmol. 2010;38:128-140.

8. Seitz B, Daas L, Flockerzi E, Suffo S. DMEK – spender und empfänger schritt für schritt. Der Ophthalmologe. 2020;117:811-828.

9. Anshu A, Price MO, Tan DTH, Price FW Jr. Endothelial keratoplasty: a revolution in evolution. Surv Ophthalmol. 2012;57:236-252.

10. Asi F, Milioti G, Seitz B. Descemet membrane endothelial keratoplasty for corneal decompensation caused by herpes simplex virus endotheliitis. J Cataract Refract Surg. 2018;44:106-108.

11. Hos D, Matthaei M, Bock F, et al. Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantation. Prog Retin Eye Res. 2019;73:100768.

12. Birbal RS, Baydoun L, Ham L, et al. Effect of surgical indication and preoperative lens status on Descemet membrane endothelial keratoplasty outcomes. Am J Ophthalmol. 2020;212:79-87.

13. Flockerzi E, Maier P, Böhringer D, et al. Trends in corneal transplantation from 2001 to 2016 in Germany: a report of the DOG-section cornea and its keratoplasty registry. Am J Ophthalmol. 2018;188:91-98.

14. Kinoshita S, Koizumi N, Ueno M, et al. Injection of cultured cells with a ROCK inhibitor for bullous keratopathy. N Engl J Med. 2018;378:995-1003.

15. Numa K, Imai K, Ueno M, et al. Five-year follow-up of first 11 patients undergoing injection of cultured corneal endothelial cells for corneal endothelial failure. Ophthalmology. 2021;128:504-514.

16. Moloney G, Congote DG, Hirnschall N, et al. Descemet stripping only supplemented with topical ripasudil for Fuchs endothelial dystrophy 12-month outcomes of the Sydney Eye Hospital Study. Cornea. 2021;40:320-326.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.